Patents Examined by M Franco G Salvoza
  • Patent number: 10835598
    Abstract: An experiment has shown that ranpirnase is a microbicide. It is believed that topical application of a topical pharmaceutical composition consisting essentially of a prophylactically effective concentration of an enzymatically-active ribonuclease (e.g. ranpirnase) and a viscous vehicle that does not unacceptably interfere with the enzymatic activity (e.g. K-Y® Brand Jelly) will prophylactically protect an individual from a sexually-transmitted viral infection, particularly HIV. It is also believed that e.g. ranpirnase can be delivered to tissues of an individual who is to be prophylactically protected against viral infections by transfecting ranpirnase DNA into human microbiota and exposing the individual to the thus-modified human microbiota. It is also believed that ranpirnase can be delivered to a woman who is to be prophylactically protected against a sexually-transmitted viral infection by use of an intravaginal ring that has been impregnated with ranpirnase.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: November 17, 2020
    Assignee: ORGENESIS INC.
    Inventors: Jamie Sulley, Luis Squiquera, David Sidransky, Tom Hodge
  • Patent number: 10835599
    Abstract: The present invention relates, in general, to an HIV-1 vaccine and, in particular, to a B cell lineage-based vaccination protocol.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: November 17, 2020
    Assignees: DUKE UNIVERSITY, CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Barton F. Haynes, Garnett Kelsoe, Stephen Harrison, Thomas B. Kepler
  • Patent number: 10822397
    Abstract: This invention provides antibodies or fragments thereof that are capable of specifically binding to at least one conformational epitope of Human Enterovirus 71 (EV71), wherein the antibody individually comprises at least one variable light chain and at least one variable heavy chain. There is also provided a method of producing an antibody capable of specifically binding to at least one conformational epitope of Human Enterovirus 71 (EV71).
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: November 3, 2020
    Assignee: MAB Explorations Sdn Bhd
    Inventor: Mary Jane Cardosa
  • Patent number: 10813977
    Abstract: Compositions, methods and kits are provided for treating complement related disorders in a subject with protein in combination having protein fusions of at least two of a CD46 protein, a CD55 protein and a CD59 protein or with a recombinant chimeric protein having at least two of a CD46 protein, a CD55 protein and a CD59 protein or with nucleic acids encoding these proteins. The composition negatively modulates classical and alternative complement pathways thereby treating complement related disorder such as macular degeneration, age-related macular degeneration, diabetic retinopathy, inflammatory bowel disease, thyroiditis, cryoglobulinaemia, fetal loss, organ graft rejection, cancer, etc.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: October 27, 2020
    Assignee: Trustees of Tufts College
    Inventors: Rajendra Kumar-Singh, Derek Leaderer, Siobhan Cashman
  • Patent number: 10806781
    Abstract: Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: October 20, 2020
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Jill A. Livengood, Laszlo Varga
  • Patent number: 10806779
    Abstract: Described are methods for preparing virosomes comprising the steps of: (a) providing an enveloped virus, and optionally inactivating the virus; (b) solubilizing the viral envelopes in a first solubilizing agent; (c) pre-solubilizing exogenous components in a second solubilizing agent; (d) adding the pre-solubilized exogenous components to the solubilized viral envelopes; and (e) reconstituting virosomal membranes by removing the solubilizing agent. According to the disclosure, the viral envelopes and the exogenous components are (pre-)solubilized at a temperature below 33° C.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: October 20, 2020
    Assignee: JANSSEN VACCINES & PREVENTION B.V.
    Inventors: Wenyu Dong, Pieter Rijken, Mike Ugwoke
  • Patent number: 10799568
    Abstract: The present invention relates to adenoviral vectors, wherein the viral capsid has been coated with polypeptides, which are capable of stimulating a peptide-specific immune response in a subject and uses thereof. Furthermore, the present invention relates to methods of treating diseases, e.g. cancer, by adenoviral vectors which have been coated by polypeptides causing peptide-specific immune response. Also the present invention relates to a method of coating adenoviral vectors by specific peptides as well as to a method of identifying those peptides suitable for coating the capsid of an adenoviral vector.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: October 13, 2020
    Assignee: VALO THERAPEUTICS OY
    Inventors: Vincenzo Cerullo, Markus Vähä-Koskela, Mari Hirvinen, Cristian Capasso
  • Patent number: 10781427
    Abstract: The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: September 22, 2020
    Assignees: Beth Israel Deaconess Medical Center, Inc., Washington University
    Inventors: Dan H. Barouch, Herbert Virgin, IV, Peter Abbink
  • Patent number: 10781459
    Abstract: Provided herein are methods related to co-packaging of multiple rAAV particles, e.g., by introducing multiple nucleic acid vectors encoding proteins or polypeptides or RNAs of interest into a single cell preparation.
    Type: Grant
    Filed: June 20, 2015
    Date of Patent: September 22, 2020
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Barry John Byrne, Phillip A. Doerfler, Nathalie Clement
  • Patent number: 10772951
    Abstract: The present disclosure concerns an oncolytic virus for the treatment of cancer, such as in brain cancer, for example glioblastoma. The oncolytic virus may exhibit reduced levels of neurotoxicity. The oncolytic virus may be an isolated viral particle capable of producing a cDNA polynucleotide that includes a sequence according to SEQ ID NO: 1 when the virus is in a host cell. The oncolytic virus may be an isolated viral particle that includes an RNA polynucleotide that includes a sequence according to SEQ ID NO: 2. The oncolytic virus may be an isolated viral particle having a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6 and 7; or variants thereof.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: September 15, 2020
    Assignee: CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC.
    Inventor: David F. Stojdl
  • Patent number: 10766948
    Abstract: The present invention refers to monoclonal antibodies, or fragments thereof, which recognize the pIII protein of the Adenovirus (ADV), useful for developing diagnostic methods of ADV infection in humans. Particularly, it refers to a monoclonal antibody or fragment thereof comprising a variable region of the heavy chain having a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 1 or SEQ ID No: 5 and a variable region of the light chain having a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 2 or SEQ ID No: 6. It also is addressed to the nucleotide sequences which define said antibodies, in vitro and/or ex vivo diagnostic methods of ADV infection in a biological sample using said monoclonal antibodies, and diagnostic kits for detecting ADV comprising at least one monoclonal antibody against ADV according to the above description.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: September 8, 2020
    Assignee: PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE
    Inventors: Susan Marcela Bueno Ramirez, Alexis Mikes Kalergis Parra, Jorge Eugenio Mora Alarcon
  • Patent number: 10751398
    Abstract: Compositions and treatments for inducing tumor regression by activating inflammasomes in tumor cells and tumor-associated cells. A tumor in a subject is treated by administering a composition to the subject that activates inflammasomes in cells of the tumor and thereby causes tumor cell pyroptosis and tumor regression.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: August 25, 2020
    Assignee: Loyola University Chicago
    Inventors: Liang Qiao, Zhenyu Zhong, Yougang Zhai
  • Patent number: 10745474
    Abstract: The present disclosure provides methods of treating a pathogen-induced lung inflammation in a subject are provided in which an anti-S100A9 antibody is administered to a subject. Methods of treating a respiratory virus infection by administering an anti-S100A9 antibody are also provided.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: August 18, 2020
    Assignees: Washington State University, The Board of Regents of the University of Texas Systems
    Inventors: Santanu Bose, Philippe Tessier
  • Patent number: 10736844
    Abstract: The present disclosure provides compositions and methods useful for treating viral infections. As described herein, the compositions and methods are based on the development of immunogenic compositions that include an attenuated or inactivated virus in combination with a non-ionic surfactant vesicle (NISV).
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: August 11, 2020
    Assignee: VARIATION BIOTECHNOLOGIES INC.
    Inventors: David E. Anderson, Tanvir Ahmed, Jasminka Bozic, Marc Kirchmeier
  • Patent number: 10738283
    Abstract: The invention relates to a recombinant adenovirus that has an oncolytic effect in a cancer cell. By modulating the level and type of splice isoforms of the E1B gene product, expressed from the E1B gene, the oncolytic activity of such viruses can be enhanced. The invention provides a recombinant adenovirus in which the proportion of the E1B-156R isoform is increased relative to wild-type levels. Such a recombinant adenovirus may selectivity replicate in cancer cells, thereby killing cancer cells whilst sparing normal cells.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: August 11, 2020
    Assignee: Ixogen Ltd.
    Inventor: Hans Daniel Öberg
  • Patent number: 10729784
    Abstract: The present invention relates to expressing RNA in cells and, in particular, enhancing viability of cells in which RNA is to be expressed. Specifically, the present invention provides methods for expressing RNA in cells comprising the steps of preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells. Thus, preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells allows repetitive transfer of RNA into the cells.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: August 4, 2020
    Assignees: TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSM, BIONTECH RNA PHARMACEUTICALS GMBH
    Inventors: Ugur Sahin, Tim Beissert, Marco Poleganov, Stephanie Herz, Lars Koste
  • Patent number: 10729761
    Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: August 4, 2020
    Assignee: CureVac AG
    Inventors: Karl-Josef Kallen, Thomas Kramps, Margit Schnee, Benjamin Petsch, Lothar Stitz
  • Patent number: 10722571
    Abstract: This invention relates to a rabies virus G protein epitope and a rabies-virus-neutralizing binding molecule that binds specifically thereto, wherein different epitope sites of rabies virus G protein are identified and binding molecules that bind thereto and a cocktail thereof can be found to retain neutralizing activity against various rabies viruses.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: July 28, 2020
    Assignee: Celltrion Inc.
    Inventors: Shin Jae Chang, Soo Young Lee, Pan Kyeom Kim, Jung Sun Ahn, Min Joo Choo
  • Patent number: 10718781
    Abstract: In one aspect, the present invention provides, for example, an improved method for identifying an epitope on a protein, comprising the following steps: (A) contacting a major histocompatibility complex (MHC molecule)-expressing cell differentiated from a stem cell or a progenitor cell derived therefrom with a target protein; (B) isolating a complex of a peptide contained in the target protein and the MHC molecule from the MHC molecule-expressing cell; and (C) eluting the peptide from the complex and identifying the peptide.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: July 21, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoaki Inoue, Shunsuke Ito, Nobuo Sekiguchi
  • Patent number: 10702541
    Abstract: A composition and method for activating immune cells ex-vivo, or inducing an immune response in a subject including a composition comprising at least one chiral cationic lipid. The chiral cationic lipid in one embodiment comprises a nonsteroidal cationic lipid having a structure represented by formula (I); wherein in R1 is a quaternary ammonium group, Y1 is a spacer chosen from a hydrocarbon chain, an ester, a ketone, and a peptide, C* is a chiral carbon, R2 and R3 are independently chosen from a saturated fatty acid, an unsaturated fatty acid, an ester-linked hydrocarbon, phosphor-diesters, and combinations thereof.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: July 7, 2020
    Assignee: PDS Biotechnology Corporation
    Inventors: Elizabeth Ann Vasievich, Weihsu Claire Chen, Kenya N. Toney Johnson, Gregory Conn, Frank Bedu-Addo, Leaf Huang